- Related Products
MedEx answers any queries you might have regarding Oxaliplatin-150 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Pharmacological effect of Oxaliplatin 150mg
Oxaliplatin belongs to the antitumor agents, whose platinum atom is linked to oxalate in the structure.
Aqua metabolites of Oxaliplatin, generated during the biotransformation, create the DNA structure in the interior connections, thereby suppressing the synthesis. The clinical effect of Oxaliplatin is reflected in its cytotoxic and antineoplastic effect.
During the 2-hour intravenous infusion of Oxaliplatin solution, 15% of the introduced active substance enters the bloodstream, and the rest of the drug is redistributed in tissues. The active component of the drug irreversibly binds to erythrocytes and plasma albumin. After the biotransformation with Oxaliplatin, its active (diaqua derivatives of DACH-platinum, mono- and dichloro-metabolites) and inactive conjugates are identified in the blood plasma. During the first 48 hours after the beginning of treatment with Oxaliplatin, a large share of platinum is excreted with urine.
Indications for use of Oxaliplatin 150mg
Oxaliplatin is used in combination with fluoropyrimidines for the treatment of metastatic colorectal cancer.
In case of disseminated colorectal cancer, Oxaliplatin is recommended both for a monotherapy and for a combination treatment.
Oxaliplatin is also used as a second-line drug for the treatment of ovarian cancer.
Dosage and way of use of Oxaliplatin 150mg
Oxaliplatin can be used only by the adult patients in the form of a single 2–6-hour infusion (150 mg/m2) with a 3-week break, or 85 mg/m2 (once in two weeks). If you use Oxaliplatin in combination with fluoropyrimidines (as a part of tumor therapy), it should be introduced firstly. Oxaliplatin therapy doesn’t require preliminary hyper hydration.
The dosage correction is made depending on the clinical response and expression of side effects.
In case of continuing paresthesia without additional functional impairments, the drug should be introduced in the amount of 65 mg/m2 (metastatic therapy) or 75 mg/m2 (auxiliary treatment).
In case of 4 stage of diarrhea, 3–4 stage of neutropenia (lower 1,0 x 109/l), as well as the 3–4 stage of thrombocytopenia (lower 50 x 109/l), the dose of Oxaliplatin should be reduced from 85 to 65 mg/m2 (in case of metastasis) or 75 mg/m2 (for a second-line treatment). In case of combination treatment, the dosage of fluoropyridimine is also reduced according to the instruction.